tirzepatide list Compounders protest as FDA removes off shortage FDA says 'no clinical need'

As KFF noted in its policy analysis: "It is uncertain how participating beneficiaries will be able to maintain Medicare coverage of their GLP-1 medication for obesity after the Medicare GLP-1 Bridge ends at the end of 2027." What We Know So Far The Medicare GLP-1 Bridge is a federal demonstration program, not a Part D benefit

UKB: OR = 1.00, 95% CI [0.990.99]

Patients should use non-oral contraceptive methods or add a barrier method for 4 weeks after tirzepatide initiation and after each dose increase

The LMN should explicitly say requested for moderate-to-severe OSA per FDA-approved indication based on SURMOUNT-OSA. Cite the polysomnography results